The Eli Lilly CEO says inflammation is the next frontier
The Eli Lilly CEO says inflammation is the next frontier. For an autoimmune family, that's familiar ground.
Most of the coverage of his hour on Scott Galloway's podcast was about the money — a trillion-dollar company, weight-loss drugs everywhere. For a family living with an autoimmune condition, the parts worth your time were somewhere else: what the research is quietly chasing, how to think clearly about what you read, and — at the very end — what he said about being a father.
If you live in an autoimmune body — and if you're reading this, you or someone you love almost certainly does — there was a moment in this interview worth more than the trillion-dollar headline it got buried under.
David Ricks, the CEO of Eli Lilly, was talking about where GLP-1 drugs might go next, and one of the frontiers he named lands right where we live: inflammation. He didn't use the word "autoimmune." But you can't talk about one without brushing up against the other.
The inflammation thread
Ricks ran through several places these drugs might go next — metabolic and cardiovascular disease, addiction (drinking, smoking, gambling), and early, unproven signals on cancer. The one that's our neighborhood is inflammation. On top of obesity, he said, "America is in an inflammatory crisis" — and he pointed at asthma, psoriasis, and arthritis as the chronic inflammatory conditions the research is moving toward. He even described obesity and inflammation as "close travelers."
Here's the connection he didn't make, but we can. Autoimmune conditions are, underneath everything, inflammation stories — the immune system inflaming and turning on the body's own tissue. Type 1 is that. The thyroid disease so many of us also carry is that. Celiac is that. And if there's one thing this community knows in its bones, it's that autoimmune conditions travel in packs too. So when the most valuable healthcare company on earth names inflammation among the places these drugs are headed, we have a reason to listen — not as patients waiting for a prescription, but as people who already live on the ground the research is walking toward.
Nobody in that interview claimed these drugs do anything for the autoimmune process behind type 1, and I'm not claiming it either. There is no "GLP-1 fixes your diabetes" here, and the day you hear that sentence from anyone, walk away from it. None of this is medical advice, and nothing here is a reason to change a single thing you're doing. The point is gentler and more interesting than a miracle: the attention, the money, and the science are turning toward inflammation — and inflammation is the soil our conditions grow in. That's worth understanding. It isn't something to act on.
What's interesting about the drugs themselves
Ricks made one point that's underappreciated. Most medications, he said, work "on average" — they help some people and not others. He believes this class is different: it works for nearly everyone, and — the unusual part — people like being on it. That runs against how most chronic-disease medicine feels. You usually take something, feel a little worse, definitely feel a little poorer, and get told you're preventing something years away. A medication people don't fight to quit is a different kind of thing.
The claims worth holding loosely
A few of his statements are striking enough to repeat — as long as we're clear they're claims, not settled facts. He's a CEO with a product to sell. Here they are.
He said their next, more powerful drug — a triple-acting version of these same GLP medicines, the one he's hoping to launch next year — came back as the most powerful pain reducer ever tested pharmacologically, on arthritic knee pain. Same family, scaled up, which is what makes the inflammation thread tighter rather than looser. He pointed to lower cancer rates in people who'd been on these drugs for years, and flagged that finding himself as observational — a pattern someone noticed, not a cause anyone has proven. And the reports of reduced drinking, smoking, and gambling are early — some noticed in trials, some just what people say about themselves. Promising, not proven — worth knowing, not worth banking on.
On "peptides," and how we read what we read
This is the part most relevant to our community, because it's really about us — people who share what worked for them, and who sometimes go looking on their own when the system comes up short. Ricks was blunt about the online "peptide" market. His term for the unregulated stuff was "unstudied medicines" — no trials, no safety data, no FDA. And the caution underneath it: leaning on what he called "N-of-one anecdotes," one person saying it helped me, and treating that as proof.
I want to handle this carefully, because I host a podcast built largely on people sharing their experience. So here's the line as I see it. There's a real difference between a community comparing notes on how to better use an approved medication a doctor prescribed — and buying an unstudied chemical off the internet because a stranger swore by it. The first is people filling a gap the clinical world left wide open. The second is rolling dice with your body. Both come from the same place.
Ricks didn't just scold people for going looking, though — he named why they do. No one can tell you the price. You wait in line. You often feel unheard. People don't strike out on their own because they're careless; they do it because the front door is hard to open and nobody will tell them what's on the other side. We know that feeling better than most. What I take from it isn't "trust the system" or "trust the internet." It's to keep curiosity and caution in the same hand.
And the money, since that's what the headlines led with
Eli Lilly just became the first healthcare company worth a trillion dollars, and by Galloway's count, about two-thirds of its sales now come from GLP-1s. This is also the company that made insulin commercially available back in 1923. So the company many of us depend on for the thing that keeps us alive is now, by its own math, mostly a weight-and-metabolic business. I don't say that as an accusation — it's just the map, and it helps to know where you're standing on it. Insulin isn't the center of that company's universe anymore. The center is wherever the inflammation research goes, which, as I said up top, is our part of town.
The part I keep thinking about
Near the end, Galloway moved the conversation to family, and this is the section I'd hand to people. Ricks has three kids and raised them in a dual-career household where the in-the-room-together time was limited, so he's clearly thought about where connection really comes from. His answer wasn't the big moments. It was the small, boring ones. The walk. Throwing a ball in the yard. He said standing on the sideline cheering is good to do, but he's not sure it's where you connect — you connect side by side, doing something ordinary, with half your brain, when there's finally room to just talk.
For anyone raising a kid with type 1, there's a catch in that. So much of our side-by-side time gets quietly eaten — by the site change, the number on the screen, the math at the table, the 2 a.m. check. The ordinary moments are still there, but the disease keeps trying to move into them.
That is the whole reason I care so much about people getting good at this. Not so you can become an expert for its own sake. So that the diabetes recedes far enough into the background that you get the boring walk back — so the ball in the yard is just a ball in the yard. Competence was never the goal. It's what buys you the ordinary day.
This is my commentary on an interview with David Ricks, Chair & CEO of Eli Lilly, on The Prof G Pod with Scott Galloway. All quotes belong to the speakers; go listen to the full conversation for everything in context.
Nothing here is an endorsement of any medication, and any health claims described are those of the interview's speakers, not the Juicebox Podcast.
Read the full disclaimer
How strong is "the most powerful pain reducer ever tested"?
The drug is retatrutide — Lilly's once-weekly, triple-hormone agonist (it hits the GIP, GLP-1, and glucagon receptors at once). The pain claim comes from a Phase 3 trial called TRIUMPH-4: 445 adults with obesity and knee osteoarthritis, run against placebo over 68 weeks, with topline results out in December 2025.
The numbers are striking. At the top dose, people lost about 28.7% of their body weight — north of 70 pounds on average — and their knee-pain scores fell by as much as roughly three-quarters. About one in eight finished the trial completely free of knee pain, against roughly one in twenty-five on placebo.
Here's the part the superlative skips. The knee almost certainly feels better mostly because there's far less weight pressing on it. Line retatrutide up next to semaglutide and the bigger pain drop tracks the bigger weight loss — which points to load coming off the joint, not some brand-new painkiller. That's no comfort lost for the person whose knee stopped hurting. But "most powerful pain reducer ever tested" is doing some marketing work: it's a cross-trial comparison, not a head-to-head, and it's a weight-loss story at least as much as a pain story.
And it's early. This is topline data — the full results haven't been peer-reviewed or published, and the drug isn't approved for anything yet; Lilly says it plans to ask the FDA to include knee osteoarthritis among retatrutide's first uses in late 2026. The trial also logged real downsides: heavy nausea and diarrhea, and abnormal skin sensations (dysesthesia) in roughly one in five people at the top dose.
So — a big, real result, aimed at something that wrecks a lot of lives, and worth watching. Just not the finished, free-standing miracle the phrase makes it sound like. Promising, not proven, same as the rest.
Newest Episode
Catch the latest from the Juicebox Podcast
Subscribing / Following is Supporting
1,800+ Episodes · Bold With Insulin
